Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.55 |
| ▸ | FLT1 | P17948 | 5/20 | 0.55 |
| ▸ | FLT4 | P35916 | 5/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | ARAF | P10398 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469549 | 0.93 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL278844 | 0.88 | KDR (0.55) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2471584 | 0.87 | KDR (0.68) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2465036 | 0.85 | KDR (0.56) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2470938 | 0.84 | KDR (0.61) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468856 | 0.84 | KDR (0.75) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL274104 | 0.84 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468872 | 0.80 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2465925 | 0.78 | KDR (0.65) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2469664 | 0.78 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | claimed |